Syensqo reported Q1 2026 net sales of €1.4 billion, up 5% sequentially driven by Specialty Polymers and Novecare, despite a 7.4% year-on-year decline impacted by foreign exchange. Underlying EBITDA rose 6% sequentially to €251 million, though it fell 13% organically year-on-year. The company completed the divestment of its Oil & Gas unit and lowered its 2026 capital expenditure forecast by up to €50 million, maintaining an underlying EBITDA outlook of approximately €1.1 billion. Syensqo expects low single-digit volume growth for 2026, with improving order trends in Q2 supporting confidence in meeting full-year targets.
ImPact Biotech announced updated Phase 3 ENLIGHTED trial results showing 70% complete response in patients with low-grade upper tract urothelial carcinoma (UTUC) treated with Padeliporfin VTP. The treatment demonstrated durable effects, with 85.7% of...
EdgeX has dropped 10% amid strong bearish momentum, with technical indicators like Parabolic SAR and Aroon signaling further declines. The price has broken a key support trendline and is heading toward a critical demand zone that previously triggered...
The Russell 2000 index, representing small-cap U.S. stocks, fell 2.4% on Friday, marking its worst one-day decline since November 13. Despite this setback, small caps have outperformed most major indexes except the Nasdaq in 2026. The recent rise in ...
The NEOS Nasdaq-100 High Income ETF (QQQI) uses a covered call strategy that limits upside gains and offers only modest protection against losses, making it vulnerable in prolonged bear markets. While the fund attracts investors with its attractive m...
Luca Socci presents a framework to evaluate the economic productivity of $725 billion in AI-focused capital expenditures by hyperscalers, with 75% being AI-specific. His method separates direct profits from suppliers and enabled profits from AI-depen...
